2CARSON S W.Pharmacokinetic and pharmacodynamic drug interactions with polyphannocotherapy of treatment-resistant affective and obsessive-compulsive disorders[J].Psycopharmacol Bull,1996.32:555-568.
3SHADER R I.VON MOIJTKE L L,SCHMIDER J,et al.The clinician and drug interactions an update[J].J Clin Psychopharmacol.1996,16:197.201.
4POND SM,GRAHAM GG,BIRKETFD J,et al.Effects of tricyclic antidepressants on drug metabolism[J].Clin Pharmacol Ther,1975,18(2):191-199.
5THOMPSON D S,SWEET R A,MARZULA K,et al.Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient[J].J Clin Psychopharmacol,1997,17(4):322-323.
6FLEISHAKER J C,RYAN K K,JANSAT J M,et al.Effect of MAO2A inhibition on the pharmacokinetics of almotriptan,an antimigraine agent in humans[J].Br J Clin Phartrmacol,2001,51:437-441.
7HARVEY P.Cytochrome P450 enzymes:interpretation of their interactions with selective serotonin reuptake inhibitom.Part I[J].J Clin Psychopharmacol,1996,16:273-285.
8NELSON M H,BIRNBAUM A K,REMMEL R P Inhibition of phenytoin hydroxylation in human liver microsomes by several selective semtonin re-uptake inhibitors[J].Epilepsy Res,2001,44(1):71-82.
9CAI W M,CHEN B,ZHOU Y,et al.Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers[J].Clin Pharmacol Ther,1999,66(5):516-521.
